PMC:7195088 / 45577-46224 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1357","span":{"begin":30,"end":43},"obj":"Gene"},{"id":"1358","span":{"begin":140,"end":148},"obj":"Species"},{"id":"1359","span":{"begin":256,"end":264},"obj":"Species"},{"id":"1360","span":{"begin":338,"end":346},"obj":"Species"},{"id":"1361","span":{"begin":573,"end":581},"obj":"Species"},{"id":"1362","span":{"begin":73,"end":82},"obj":"Species"},{"id":"1363","span":{"begin":454,"end":463},"obj":"Species"},{"id":"1364","span":{"begin":637,"end":646},"obj":"Species"},{"id":"1365","span":{"begin":0,"end":11},"obj":"Chemical"},{"id":"1366","span":{"begin":16,"end":25},"obj":"Chemical"},{"id":"1367","span":{"begin":193,"end":204},"obj":"Chemical"},{"id":"1368","span":{"begin":209,"end":218},"obj":"Chemical"},{"id":"1369","span":{"begin":370,"end":381},"obj":"Chemical"},{"id":"1370","span":{"begin":131,"end":139},"obj":"Disease"},{"id":"1371","span":{"begin":323,"end":337},"obj":"Disease"},{"id":"1372","span":{"begin":352,"end":360},"obj":"Disease"},{"id":"1373","span":{"begin":422,"end":431},"obj":"Disease"},{"id":"1374","span":{"begin":436,"end":447},"obj":"Disease"},{"id":"1375","span":{"begin":564,"end":572},"obj":"Disease"}],"attributes":[{"id":"A1357","pred":"tao:has_database_id","subj":"1357","obj":"Gene:4758"},{"id":"A1358","pred":"tao:has_database_id","subj":"1358","obj":"Tax:9606"},{"id":"A1359","pred":"tao:has_database_id","subj":"1359","obj":"Tax:694009"},{"id":"A1360","pred":"tao:has_database_id","subj":"1360","obj":"Tax:9606"},{"id":"A1361","pred":"tao:has_database_id","subj":"1361","obj":"Tax:9606"},{"id":"A1362","pred":"tao:has_database_id","subj":"1362","obj":"Tax:11520"},{"id":"A1363","pred":"tao:has_database_id","subj":"1363","obj":"Tax:11520"},{"id":"A1364","pred":"tao:has_database_id","subj":"1364","obj":"Tax:11520"},{"id":"A1365","pred":"tao:has_database_id","subj":"1365","obj":"MESH:D053139"},{"id":"A1366","pred":"tao:has_database_id","subj":"1366","obj":"MESH:D053243"},{"id":"A1367","pred":"tao:has_database_id","subj":"1367","obj":"MESH:D053139"},{"id":"A1368","pred":"tao:has_database_id","subj":"1368","obj":"MESH:D053243"},{"id":"A1369","pred":"tao:has_database_id","subj":"1369","obj":"MESH:D053139"},{"id":"A1370","pred":"tao:has_database_id","subj":"1370","obj":"MESH:C000657245"},{"id":"A1371","pred":"tao:has_database_id","subj":"1371","obj":"MESH:D016638"},{"id":"A1372","pred":"tao:has_database_id","subj":"1372","obj":"MESH:C000657245"},{"id":"A1373","pred":"tao:has_database_id","subj":"1373","obj":"MESH:D007239"},{"id":"A1374","pred":"tao:has_database_id","subj":"1374","obj":"MESH:D060085"},{"id":"A1375","pred":"tao:has_database_id","subj":"1375","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Oseltamivir and zanamivir are neuraminidase inhibitors used for treating influenza which are also being tested in RCT for treating COVID-19 patients (Table 2). However, no apparent activity of oseltamivir and zanamivir has previously been observed against SARS-CoV-1 in vitro [27], and the fact that up to 76% of the first critically ill patients with COVID-19 received oseltamivir may also be related to the suspicion of infection (or coinfection) with influenza [28]. Overall, this information is currently insufficient for supporting the use of these agents in COVID-19 patients unless in the presence of suspected/proven concomitant influenza."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T250","span":{"begin":73,"end":82},"obj":"Disease"},{"id":"T251","span":{"begin":131,"end":139},"obj":"Disease"},{"id":"T252","span":{"begin":256,"end":264},"obj":"Disease"},{"id":"T253","span":{"begin":352,"end":360},"obj":"Disease"},{"id":"T254","span":{"begin":422,"end":431},"obj":"Disease"},{"id":"T255","span":{"begin":454,"end":463},"obj":"Disease"},{"id":"T256","span":{"begin":564,"end":572},"obj":"Disease"},{"id":"T257","span":{"begin":637,"end":646},"obj":"Disease"}],"attributes":[{"id":"A250","pred":"mondo_id","subj":"T250","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A251","pred":"mondo_id","subj":"T251","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A252","pred":"mondo_id","subj":"T252","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A253","pred":"mondo_id","subj":"T253","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A254","pred":"mondo_id","subj":"T254","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A255","pred":"mondo_id","subj":"T255","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A256","pred":"mondo_id","subj":"T256","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A257","pred":"mondo_id","subj":"T257","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"}],"text":"Oseltamivir and zanamivir are neuraminidase inhibitors used for treating influenza which are also being tested in RCT for treating COVID-19 patients (Table 2). However, no apparent activity of oseltamivir and zanamivir has previously been observed against SARS-CoV-1 in vitro [27], and the fact that up to 76% of the first critically ill patients with COVID-19 received oseltamivir may also be related to the suspicion of infection (or coinfection) with influenza [28]. Overall, this information is currently insufficient for supporting the use of these agents in COVID-19 patients unless in the presence of suspected/proven concomitant influenza."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T265","span":{"begin":104,"end":110},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T266","span":{"begin":181,"end":189},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T267","span":{"begin":219,"end":222},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T268","span":{"begin":277,"end":279},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"}],"text":"Oseltamivir and zanamivir are neuraminidase inhibitors used for treating influenza which are also being tested in RCT for treating COVID-19 patients (Table 2). However, no apparent activity of oseltamivir and zanamivir has previously been observed against SARS-CoV-1 in vitro [27], and the fact that up to 76% of the first critically ill patients with COVID-19 received oseltamivir may also be related to the suspicion of infection (or coinfection) with influenza [28]. Overall, this information is currently insufficient for supporting the use of these agents in COVID-19 patients unless in the presence of suspected/proven concomitant influenza."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T553","span":{"begin":0,"end":11},"obj":"Chemical"},{"id":"T554","span":{"begin":16,"end":25},"obj":"Chemical"},{"id":"T555","span":{"begin":30,"end":54},"obj":"Chemical"},{"id":"T556","span":{"begin":44,"end":54},"obj":"Chemical"},{"id":"T557","span":{"begin":193,"end":204},"obj":"Chemical"},{"id":"T558","span":{"begin":209,"end":218},"obj":"Chemical"},{"id":"T559","span":{"begin":370,"end":381},"obj":"Chemical"}],"attributes":[{"id":"A553","pred":"chebi_id","subj":"T553","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A554","pred":"chebi_id","subj":"T554","obj":"http://purl.obolibrary.org/obo/CHEBI_50663"},{"id":"A555","pred":"chebi_id","subj":"T555","obj":"http://purl.obolibrary.org/obo/CHEBI_52425"},{"id":"A556","pred":"chebi_id","subj":"T556","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A557","pred":"chebi_id","subj":"T557","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A558","pred":"chebi_id","subj":"T558","obj":"http://purl.obolibrary.org/obo/CHEBI_50663"},{"id":"A559","pred":"chebi_id","subj":"T559","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"}],"text":"Oseltamivir and zanamivir are neuraminidase inhibitors used for treating influenza which are also being tested in RCT for treating COVID-19 patients (Table 2). However, no apparent activity of oseltamivir and zanamivir has previously been observed against SARS-CoV-1 in vitro [27], and the fact that up to 76% of the first critically ill patients with COVID-19 received oseltamivir may also be related to the suspicion of infection (or coinfection) with influenza [28]. Overall, this information is currently insufficient for supporting the use of these agents in COVID-19 patients unless in the presence of suspected/proven concomitant influenza."}

{"project":"LitCovid-sentences","denotations":[{"id":"T362","span":{"begin":0,"end":159},"obj":"Sentence"},{"id":"T363","span":{"begin":160,"end":469},"obj":"Sentence"},{"id":"T364","span":{"begin":470,"end":647},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Oseltamivir and zanamivir are neuraminidase inhibitors used for treating influenza which are also being tested in RCT for treating COVID-19 patients (Table 2). However, no apparent activity of oseltamivir and zanamivir has previously been observed against SARS-CoV-1 in vitro [27], and the fact that up to 76% of the first critically ill patients with COVID-19 received oseltamivir may also be related to the suspicion of infection (or coinfection) with influenza [28]. Overall, this information is currently insufficient for supporting the use of these agents in COVID-19 patients unless in the presence of suspected/proven concomitant influenza."}

{"project":"2_test","denotations":[{"id":"32360444-15200845-22369767","span":{"begin":277,"end":279},"obj":"15200845"},{"id":"32360444-32007143-22369768","span":{"begin":465,"end":467},"obj":"32007143"}],"text":"Oseltamivir and zanamivir are neuraminidase inhibitors used for treating influenza which are also being tested in RCT for treating COVID-19 patients (Table 2). However, no apparent activity of oseltamivir and zanamivir has previously been observed against SARS-CoV-1 in vitro [27], and the fact that up to 76% of the first critically ill patients with COVID-19 received oseltamivir may also be related to the suspicion of infection (or coinfection) with influenza [28]. Overall, this information is currently insufficient for supporting the use of these agents in COVID-19 patients unless in the presence of suspected/proven concomitant influenza."}